Context Therapeutics (CNTX) Operating Income (2020 - 2026)
Context Therapeutics (CNTX) posted Operating Income of -$9.3 million for Q1 2026, up 32.31% sequentially from -$13.8 million in Q4 2025, and down 68.99% YoY from -$30.1 million in Q1 2025.
Context Therapeutics (CNTX) Operating Income (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Operating Income for 7 years, with the latest figure at -$9.3 million in Q1 2026.
- Quarterly Operating Income fell 68.99% year-over-year to -$9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.5 million (down 37.58% YoY) and the FY2025 annual result came in at -$39.7 million, down 32.68% from the prior year.
- Operating Income advanced to -$9.3 million in Q1 2026 per CNTX's latest filing, from -$13.8 million in the prior quarter.
- Over five years, Operating Income peaked at -$3.1 million in Q2 2024 and troughed at -$18.7 million in Q3 2024.
- A 5-year average of -$7.0 million and a median of -$5.5 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income slumped 309.72% in 2022, then soared 43.26% in 2025.
- Over 5 years, Operating Income stood at -$3.9 million in 2022, then plunged by 78.58% to -$6.9 million in 2023, then surged by 37.83% to -$4.3 million in 2024, then tumbled by 220.26% to -$13.8 million in 2025, then surged by 32.31% to -$9.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$9.3 million, -$13.8 million, and -$10.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 133.12 Mn |
| 10 | Context Therapeutics | 49.90 Mn | 49.90 Mn | - | -14.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.97 Mn |
| Mar 31, 2026 | -9.34 Mn |
| Dec 31, 2025 | -13.80 Mn |
| Sep 30, 2025 | -10.61 Mn |
| Jun 30, 2025 | -9.76 Mn |
| Mar 31, 2025 | -5.53 Mn |
| Dec 31, 2024 | -4.31 Mn |
| Sep 30, 2024 | -18.70 Mn |
| Jun 30, 2024 | -3.09 Mn |
| Mar 31, 2024 | -3.82 Mn |
| Dec 31, 2023 | -6.93 Mn |
| Sep 30, 2023 | -6.18 Mn |
| Jun 30, 2023 | -5.29 Mn |
| Mar 31, 2023 | -6.67 Mn |
| Dec 31, 2022 | -3.88 Mn |
| Sep 30, 2022 | -4.05 Mn |
| Jun 30, 2022 | -4.01 Mn |
| Mar 31, 2022 | -3.44 Mn |
| Dec 31, 2021 | -3.09 Mn |
| Sep 30, 2021 | -1.57 Mn |